ProfileGDS5678 / 1417896_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 43% 26% 42% 31% 25% 27% 26% 28% 27% 27% 37% 28% 34% 26% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.0311843
GSM967853U87-EV human glioblastoma xenograft - Control 22.6070126
GSM967854U87-EV human glioblastoma xenograft - Control 32.9733842
GSM967855U87-EV human glioblastoma xenograft - Control 42.6592231
GSM967856U87-EV human glioblastoma xenograft - Control 52.5422625
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.6830227
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.6421526
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.6331628
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.5860127
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.6057827
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.8456337
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.6106828
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.7818334
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.5987426